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In Brief
Prader-Willi syndrome (PWS) is a genetic
obesity syndrome. Bochukova et al.
report gene expression changes in the
hypothalamus of people with PWS that
support neurodegeneration and
neuroinflammation as key processes
involved in this condition.
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https://doi.org/10.1016/j.celrep.2018.03.018SUMMARY
Transcriptional analysis of brain tissue from people
with molecularly defined causes of obesity may high-
light disease mechanisms and therapeutic targets.
We performed RNA sequencing of hypothalamus
from individuals with Prader-Willi syndrome (PWS),
a genetic obesity syndrome characterized by severe
hyperphagia. We found that upregulated genes over-
lap with the transcriptome of mouse Agrp neurons
that signal hunger, while downregulated genes over-
lap with the expression profile of Pomc neurons
activated by feeding. Downregulated genes are
expressed mainly in neuronal cells and contribute
to neurogenesis, neurotransmitter release, and syn-
aptic plasticity, while upregulated, predominantly
microglial genes are involved in inflammatory re-
sponses. This transcriptional signaturemay bemedi-
ated by reduced brain-derived neurotrophic factor
expression. Additionally, we implicate disruption of
alternative splicing as a potential molecular mecha-
nism underlying neuronal dysfunction in PWS. Tran-
scriptomic analysis of the human hypothalamus
may identify neural mechanisms involved in energy
homeostasis and potential therapeutic targets for
weight loss.
INTRODUCTION
Neural circuits within the hypothalamus regulate energy balance
in response to peripheral nutrient-related cues (Andermann andCell R
This is an open access article undLowell, 2017; Gautron et al., 2015). Leptin-responsive Agouti-
related protein (Agrp)-expressing neurons in the arcuate nucleus
of the hypothalamus are activated during fasting or caloric deficit
to drive an increase in food intake, while in the nutritionally
replete or fed state, Pro-opiomelanocortin (Pomc) neurons are
activated to reduce food intake (Cowley et al., 1999, 2001). In
humans, loss-of-function mutations that disrupt the function of
these neural circuits result in severe obesity, demonstrating their
pivotal role in human energy homeostasis (O’Rahilly and Farooqi,
2008; van der Klaauw and Farooqi, 2015).
However, experiments in rodents (Atasoy et al., 2012; Betley
et al., 2013) and genetic studies in humans (Hendricks et al.,
2017) suggest that the neural mechanisms that regulate energy
homeostasis are complex and that many molecular components
of these circuits remain to be discovered (Sternson et al., 2016).
One potential approach to identifying genes and pathways is to
use transcriptomic analysis of key tissues and organs to identify
changes in gene expression in response to a perturbation or ge-
neticmanipulation. The specificity of these approaches has been
enhanced by recent technological developments that have
enabled the labeling, sorting, and RNA sequencing of molecu-
larly defined populations of neurons in the mouse brain. To this
end, the recent detailed analysis of high-quality gene expression
data frommouse Agrp and Pomc neurons has provided a frame-
work for investigating the genes whose expression changes with
fasting and feeding (Campbell et al., 2017; Henry et al., 2015).
Although comparable studies of specific cell types are not
feasible in humans, transcriptional analysis of hypothalamic tis-
sue from people with molecularly defined subtypes of severe
obesity has the potential to inform the discovery of neural mech-
anisms involved in energy balance. Here, we characterized the
hypothalamic transcriptome of individuals with Prader-Willi syn-
drome (PWS), a genetic obesity syndrome caused by loss ofeports 22, 3401–3408, March 27, 2018 ª 2018 The Author(s). 3401
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Genome-wide Transcriptional Changes in PWS Hypothalamus
(A) Principal-component (PC) analysis showing segregation of PWS and control hypothalamic samples.
(B) Heatmap representing the top 45 most significantly DEGs shown as within-gene Z score (left) and rlog-normalized read counts (right).
(C) Venn diagrams illustrating differentially down- and upregulated genes in PWS versus control samples in this study (discovery set) and overlap with genes from
a previous study in PWS (replication set) (Falaleeva et al., 2015).
(D) Heatmaps representing the expression of brain cell-type-specific genes among the DEGs displayed as within-gene Z score of rlog-normalized read counts.
See also Figure S1 and Table S1.expression of paternally expressed genes and noncoding RNAs
on chromosome 15q11–q13 (Cassidy et al., 2012).
RESULTS AND DISCUSSION
RNA sequencing was performed on post-mortem hypothalamic
tissue from four PWS patients and four age-matched controls
from the University of Maryland Brain and Tissue Bank (Fig-
ure S1). Although samples from controls matched for both age
and obesity were not available, the bodymass index (BMI) values
of patients and controls were comparable (Figure S1A). Prin-
cipal-component analysis revealed segregation between PWS
and control samples (Figure 1A).We identified 3,676 differentially
expressed genes (DEGs) in PWS individuals compared with con-
trols (Table S1; Benjamini-Hochberg false discovery rate [FDR] <
0.25; 658 with FDR < 0.05). The most highly downregulated
genes (FDR < 5 3 105) were located in the PWS critical region
(Figure 1B). A random subset of genes were validated by qRT-
PCR (Figure S1E). In the absence of high-quality hypothalamic
tissue for replication, we compared our data with a previous
high-density microarray study of hypothalamic gene expression3402 Cell Reports 22, 3401–3408, March 27, 2018in two PWS patients (Falaleeva et al., 2015) and found significant
overlap of dysregulated genes (Figures 1C and S1D; Table S1).
However, there was minimal overlap with datasets derived
from PWS induced pluripotent stem cell (iPSC)-derived neuronal
cell lines (data not shown); notably, we did not find reduced
expression of the obesity-associated gene PCSK1 reported
recently (Burnett et al., 2017b).
To identify the cellular origin of DEGs, we ranked genes on the
basis of their relative expression in single-cell transcriptomic
data from neurons, astrocytes, microglia, oligodendrocytes,
and endothelial cells (Supplemental Experimental Procedures).
We found that downregulated genes were enriched for neuronal
markers (p = 3 3 108), while upregulated genes were enriched
for microglial genes (p = 9 3 105) (Figure 1D). Further analysis
using CIBERSORT (Newman et al., 2015) also showed that
PWS hypothalamic tissue was characterized by a reduction in
neurons (Figure S1F). Interestingly, this cellular transcriptomic
profile aligns with that seen in autism (Parikshak et al., 2016),
in several neurodegenerative diseases, and in the aging brain
(Blalock et al., 2004; Lu et al., 2004) (Figure S2A), suggesting
that fundamental mechanisms regulating neuronal maintenance
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Figure 2. Dysregulated Gene Co-expres-
sion Modules in PWS Hypothalamus
Converge with Fasting and Feeding Re-
sponses in Specific Hypothalamic Cell
Types from Mice
(A) Venn diagrams illustrating the number of DEGs
that are down- and upregulated in PWS hypo-
thalami compared with controls and their expres-
sion in Pomc, Agrp, and other neurons (Campbell
et al., 2017; Henry et al., 2015). For comparison,
the reference gene sets (Pomc, 261 genes; Agrp,
167 genes; other neurons, 1,589 genes) are
included in Figure S2A.
(B) Number of PWS DEGs (up- or downregulated)
that are expressed in Agrp neurons in the fasted
versus fed state (q < 0.05 in Henry et al., 2015).
(C) Gene co-expression modules among upregu-
lated PWS DEGs. Hierarchical clustering of DEGs
upregulated in PWS with log2 fold change >1.5.
The heatmap illustrates pairwise gene-gene cor-
relation clustering (Pearson correlation, distance =
1-cor, Ward clustering). The sidebar (right) dis-
plays the overlap with genes previously reported
upregulated (red) or downregulated (green) in Agrp
neurons in the fasted versus fed state (q < 0.05 in
Henry et al., 2015).
See also Figure S2 and Table S1.may contribute to a range of human neurological diseases,
including PWS.
Overlap of the Human PWS Transcriptome with the
Transcriptome of Agrp Neurons in Fasting
To identify potential candidate obesity genes, we compared
PWS DEGs with genes expressed in hypothalamic Agrp and
Pomc neurons in mice (Campbell et al., 2017; Henry et al.,
2015) (Supplemental Experimental Procedures). We found that
expression of Agrp was increased 3-fold in PWS hypothalamus
versus controls (p = 0.01), suggesting this potent orexigenic
may play a role in the hyperphagia associated with PWS. Other
upregulated genes were predominantly expressed in mouse
Agrp neurons that signal hunger, while genes downregulated
in PWS were relatively overrepresented in mouse Pomc neurons
that signal the fed state (Fisher’s exact test, odds ratio [OR] = 7.2,
p = 2.3 3 104) (Figures 2A and S2). A significant number of
PWS upregulated genes were expressed inmouse Agrp neurons
and upregulated in fasted animals (Fisher’s exact test, OR = 5.3,
p = 1012; Figure 2B), suggesting that these genes represent a
conserved signature of the neural response to fasting or food
deprivation.
Using hierarchical cluster analyses of high-confidence DEGs
(absolute log fold change > 1.5), we identified sets of co-ex-
pressed genes and gene modules whose expression was upre-
gulated in Agrp neurons in the fasted state (Figure 2C). We
observed increased expression of ribosomal proteins involved
in protein synthesis. This finding aligns with the upregulation of
genes involved in endoplasmic reticulum (ER) protein transloca-
tion and Golgi trafficking seen in Agrp neurons in mice with fast-
ing (Henry et al., 2015) and may reflect increased production ofneuropeptides for secretion. Several genes downregulated in
PWS, and also in mouse Pomc neurons, were involved in synap-
tic transmission and neuronal maintenance and integrity. As
loss-of-function mutations in some of these genes (SRPX2 and
ZBTB16; Table S1) are known to cause human neurological dis-
orders, their reduced expression could contribute to both the
obesity and the neurodevelopmental phenotype of PWS.
A subset of co-regulated genes dysregulated in the PWS hy-
pothalamus are expressed in Agrp neurons in fasting and are
known to play a role in energy homeostasis and adipocyte
biology in rodents (SOCS3, ANGPTL4, FOSL1, FOSL2, and
STC2; Table S1). Interestingly, bone morphogenic factor-3
(BMP3), whose expression is markedly decreased in mouse
Agrp neurons in the fasted state (17.7-fold, q = 2.0 3 105;
Henry et al., 2015), was found to be significantly decreased in
the human PWS hypothalamus. These findings generate hypoth-
eses that will need to be explored further. Characterization of the
neurons in which these genes are expressed and the processes
they regulate, as well as DEGs expressed in other transcription-
ally distinct neuronal cell types, may provide insights into the
mechanisms involved in human energy balance.
Human PWS Hypothalamus Is Characterized by
Downregulation of Genes Involved in Neuronal Function
and Upregulation of Microglial Genes and Inflammatory
Markers
We found that downregulated DEGs were significantly enriched
for genes involved in certain processes, namely, neurogenesis,
neurotransmitter release, and synaptic function (Figure 3A). Us-
ing Ingenuity Pathway Analysis, we identified 11 potential regu-
lators of clusters of downregulated DEGs (Table S2), includingCell Reports 22, 3401–3408, March 27, 2018 3403
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Figure 3. Pathways Predicted to Be Affected by Changes in Gene Expression Seen in PWS Hypothalamus
(A) A gene annotation network illustrating terms (Gene Ontology, Reactome, Key) enriched among downregulated DEGs. Nodes represent downregulated DEGs
annotated with illustrated terms; edges join pairs of genes annotated with the respective term.
(legend continued on next page)
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the neurotrophin brain-derived neurotrophic factor (BDNF) and
its receptor, TrkB (encoded by NTRK2). Putative BDNF/TrkB tar-
gets among the downregulated DEGs were predominantly
related to synaptic processes (Figure 3B). This finding is
intriguing, as BDNF is a major regulator of the development,
maturation, andmaintenance of neurons and amodulator of syn-
aptic plasticity (Snider, 1994). Moreover, in mice and humans,
genetic disruption of BDNF and TrkB causes developmental
delay, stereotyped behaviors, impaired pain sensation, hyper-
phagia, and severe obesity (Gray et al., 2006; Yeo et al., 2004),
phenotypes that show some overlap with those seen in PWS.
We also obtained several post-mortem brain samples for
histology. Very few samples were of sufficient quality, limiting
quantitative analysis, but fluorescence in situ hybridization of
human hypothalamic tissue suggested that the number of cells
expressing BDNF and NTRK2 mRNA was reduced in the ventro-
medial nucleus of the hypothalamus in PWS (Figures 3C and S3).
We measured levels of plasma BDNF (potentially derived from
platelets) in patients with PWS versus age-matched obese con-
trols, but we did not find a significant difference (Figure S3G), in
contrast to one previous study (Han et al., 2010). Possible expla-
nations are that BDNF levels are known to vary considerably in
plasma versus serum and among assays; additionally, plasma
BDNF may not reflect BDNF expression in the brain.
A previous histopathological study of the PWS hypothala-
mus found a significantly reduced number of oxytocin neurons
(Swaab et al., 1995), and clinical trials of intranasal oxytocin
administration in PWS are ongoing (Tauber et al., 2017). In
our study, we found a low level of oxytocin mRNA and a
smaller number of cells immunoreactive for oxytocin in the
paraventricular nucleus in PWS samples (Figure 3C), support-
ing the key role of oxytocin as well as BDNF in the neuropa-
thology of PWS. Additional studies are needed to replicate
these findings and to investigate the potential loss of other
neuronal populations (including Pomc and Agrp neurons)
within the hypothalamus in PWS.
We found that upregulated genes in the PWS hypothalamus
were enriched for cytokine signaling and inflammatory pro-
cesses (Figure 3D; Table S2). The most statistically significant
predicted regulator of these genes was tumor necrosis factor
(TNF)-alpha, which plays a critical role in systemic inflamma-
tion (Figure 3E; Table S2). In the human hypothalamus, we
studied expression of S100b (a glial-specific protein marker
of neural damage) and GFAP (an astrocyte filament protein
that plays a critical role in synaptic function and is reduced
in neurodegenerative disorders but increased in brain injury).
We found that S100b protein levels were increased and(B) Ingenuity Pathway Analysis (IPA) regulator effects analysis indicates the inhib
effects on target genes and processes. Phenotypes predicted to occur as a conse
(enhanced).
(C) Representative FISH images of BDNF and NTRK2 mRNA-expressing cells in t
cells in the paraventricular nucleus of the hypothalamus in PWS and control sam
oxytocin [n = 2 PWS, n = 1 control]).
(D) A gene annotation network illustrating terms enriched among upregulated DE
(E) IPA upstream regulator analysis indicates inhibition of TNF/NFKb signaling.
(F) Representative immunohistochemistry images of S100Beta- and GFAP-immu
control samples.
See also Figure S3 and Table S2.GFAP immunoreactivity was decreased in the PWS hypothal-
amus compared with controls (Figure 3F). These findings
overlap with data from other neurodevelopmental conditions
(Griffin et al., 1989). Further studies with larger sample sizes
are needed to explore the potential relevance of these
findings.
Targeted Deletion of SNORD116 Affects Neuronal
Differentiation, Proliferation, and Survival
Chromosomal deletions that cause PWS vary in size and thus
can affect a number of genes and noncoding RNAs. None of
the mouse models involving deletion of the homologous region
fully recapitulate the human PWS phenotype (Resnick et al.,
2013); as such, investigation of the molecular mechanisms
that underlie the clinical phenotype has been challenging. The
minimal genetic lesion associated with severe hyperphagia
and obesity in PWS contains a cluster of noncoding small
nucleolar RNAs (snoRNAs) referred to as the SNORD116
gene cluster (de Smith et al., 2009; Sahoo et al., 2008). Post-
natal deletion of SNORD116 in the mediobasal hypothalamus
has recently been shown to lead to increased food intake in
mice (Polex-Wolf et al., 2018). To test whether loss of
SNORD116 affects neuronal development and maintenance,
as suggested by our transcriptomics analysis and in line with
a rodent model (Burnett et al., 2017a), we deleted a 57.4 kb
genomic segment encompassing the SNORD116 cluster using
CRISPR-Cas9 in a SH-SY5Y neuroblastoma human cell line
(Figure S4A). We found that SNORD116-deficient cells ex-
hibited reduced neuronal differentiation, cell proliferation, and
survival compared with wild-type cells (Figures 4A–4C). A
higher proportion of SNORD116-deficient cells displayed neu-
rites when treated with BDNF (mean 13%) compared with no
treatment (mean 23%, p = 0.005, two-tailed t test), whereas
no significant difference was observed within wild-type cells
(28% with no treatment, 36% with BDNF; p = 0.2, two-tailed
t test). Cumulatively, these data identify a transcriptomic signa-
ture in PWS consistent with marked hypothalamic neurodegen-
eration, which may be mediated in part by reduced expression
of the neurotrophin BDNF and its receptor, TrkB. These data
align with experiments in cortical neurons of the SNORD116
knockout mouse (Burnett et al., 2017a). Neuronal loss is asso-
ciated with a marked inflammatory response in the hypothala-
mus, which may be a primary defect, secondary to the neuro-
degenerative process or, as microglia have a role in synaptic
development and function (Barres, 2008), an inflammatory
response to disordered synaptic plasticity in the PWS
hypothalamus.ition of regulatory factors NTRK2, ADCYAP1, and BDNF (top) with predicted
quence of the gene expression changes are shown in blue (inhibited) or orange
he ventromedial nucleus of the hypothalamus and oxytocin mRNA-expressing
ples (BDNF [n = 2 PWS, n = 2 controls], NTRK2 [n = 2 PWS, n = 1 control], and
Gs. Nodes and edges as in Figure 2A.
noreactive cells in the ventromedial nucleus of the hypothalamus in PWS and
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Figure 4. Deletion of SNORD116 Impairs Neuronal Differentiation, Proliferation, and Survival
(A) Targeted deletion of SNORD116 (SNORD116del) affects the neuronal differentiation of SH-SY5Y cells, cultured for 7 days in retinoic acid (RA) in the absence
(n = 5) or presence (n = 3) of BDNF. Left: representative images of wild-type (WT) and SNORD116del cells; right: quantification plot.
(B) Cellular proliferation measured by EdU incorporation at day 7 (n = 3).
(C) Cell survival measured by FACS at day 7 in culture (n = 6).
(D) Overlap between in silico predicted SNORD116 gene targets and PWS differentially expressed and differentially spliced genes.
All data are presented as mean ± SEM. Statistical significance was measured using two-tailed Student’s t test (*p < 0.05, **p < 0.01, ***p < 0.001; ns, non-
significance). See also Figure S4 and Tables S3 and S4.Predicted snoRNA Targets and Detection of Reduced
Splicing Efficiency
SNORD116 and the closely related SNORD115 cluster belong to
a group of orphan snoRNAs with presumed non-canonical
functions. SNORD115 has been shown to regulate the post-tran-
scriptional processing of a single pre-mRNA, the serotonin 2c
receptor, through alternative splicing and RNA editing (Kishore
and Stamm, 2006). Using snoTARGET, we identified 588 pre-
dicted targets for snoRNAs within protein-coding genes (Fig-
ure 4D; Table S3), some of which were differentially expressed
in PWS hypothalamus (Figure S4B). Further studies will be
needed to test the functional significance of these findings. Inter-
estingly, RNA-specific adenosine deaminase (ADARB1), a
predicted target that is significantly downregulated (Figure S4B),
is involved in pre-mRNA editing of glutamate receptor subunit
B and when deleted causes hyperphagia and obesity in mice
(Terajima et al., 2017).
As snoRNAscanmodulateRNAsplicing (Yin et al., 2012), a pro-
cess that plays a major role in human neuronal development, we
performed a transcriptome-wide search for evidence of alterna-
tive splicing (Supplemental Experimental Procedures). We found
evidence of differential use of alternative splice variants in PWS
samples compared with controls (Table S4). Focusing on 180
loci with evidence of differential use of two alternative splice var-
iants, the most frequently observed type of splice variant in PWS
was retained introns (Table S4; Figure S4). Of note, we did not find
evidence for differential splicing of the serotonin 2c receptor (Fig-
ure S4C). Genes with putative differential splicing did not tend to3406 Cell Reports 22, 3401–3408, March 27, 2018be differentially expressed, consistent with decoupling of differ-
ential expression and splicing as seen in other disorders; excep-
tions included genes involved in microglial and inflammatory pro-
cesses, which were among the top-ranked alternatively spliced
genes (Table S4). Motif searches within retained introns and
250 bp flanking regions indicated the presence of binding sites
for canonical serine/arginine-rich splicing factors, and the pres-
ence of binding sites with predicted similarity to FUS splicing
factor binding motifs (Figure S4E). The FUS splicing factor regu-
lates alternative splicing in the brain and has been previously
linked to neurodegenerative diseases including amyotrophic
lateral sclerosis (ALS) and frontotemporal lobar degeneration
(FTLD) (Ishigaki et al., 2012; Rogelj et al., 2012).
In summary, in this study of the human hypothalamus in a
small number of individuals with PWS, we identified a transcrip-
tomic signature characterized by neuronal loss, altered neuro-
plasticity, and neuroinflammation. Of note, several neuroimaging
studies and case reports in PWS have identified structural ab-
normalities that would be consistent with a reduced number of
neurons, such as reduced gray matter volume in a number of
cortical areas and abnormal gyrification (Manning and Holland,
2015). We identify a potential role for BDNF in PWS that requires
further exploration and may have therapeutic relevance for this
complex neuro-behavioral disorder. Additionally, we demon-
strate that transcriptomic analysis of the human hypothalamus
can generate testable hypotheses of potential relevance to the
understanding of the neural circuits involved in human energy
homeostasis.
EXPERIMENTAL PROCEDURES
Human Samples
Hypothalamic specimens used in the study were obtained at autopsy from
control subjects with no reported clinical signs and patients with genetic diag-
noses of PWS through the University of Maryland Brain Bank at the University
of Maryland (Figure S1A). All procedures were approved by the University of
Cambridge Human Biology Research Ethics Committee (HBREC.2014.14).
RNA Sequencing and Analysis
Total RNA was prepared by tissue homogenization in Trizol reagent (Thermo
Fisher Scientific) of about one-third of hypothalamus. Sequencing of RNA
samples was performed by the University College London (UCL) Genomics
core facility, using the TruSeq poly-A mRNA method (Illumina) and a HiSeq
2000 machine (Illumina). Differential expression, splicing, and pathway anal-
ysis are described in detail in Supplemental Experimental Procedures, as is
the validation of DEGs using qRT-PCR.
In Silico Prediction of SNORD116 Gene Targets
Genome-wide in silico prediction of SNORD116 targets was performed using
snoTARGET software (Bazeley et al., 2008) and RNA-cofold from the Vienna
RNA package (http://www.tbi.univie.ac.at/RNA/).
Cross-Species Comparison with Agrp and Pomc Neuronal Subtypes
and Response to Food Deprivation
Reference gene sets for broad neuronal subtype classifications were derived
from Campbell et al. (2017) as described in Supplemental Experimental Pro-
cedures. Reference gene sets for fasting response in Agrp neurons were ob-
tained from Henry et al. (2015) using a threshold of q < 0.05 (unless otherwise
stated) to define differential expression between fasting conditions.
Immunohistochemistry and Fluorescence In Situ Hybridization
Immunohistochemistry was performed as reported previously (Bouret et al.,
2004) using the following primary antibodies: guinea pig anti-oxytocin (Penin-
sula Laboratories), rabbit anti-GFAP (Dako), and rabbit anti-s100beta (Abcam).
Secondary antibodies were Alexa Fluor 488 donkey anti-guinea-pig IgGs or
Alexa Fluor 488 goat anti-rabbit IgGs (Thermo Fisher Scientific). For the fluo-
rescence in situ hybridization (FISH) experiments, sense and antisense digox-
igenin-labeled riboprobes were generated from plasmids containing PCR frag-
ments of BDNF and NTRK2 (generously provided by Dr. Baoji Xu, The Scripps
Research Institute). Staining density and cell number were calculated using
ImageJ analysis software (NIH). Full details are presented in Supplemental
Experimental Procedures.
Cellular Studies
SH-SY5Y (ATCC CRL-2266) cells were used in all the cellular assays. We used
a well-established protocol to differentiate SH-SY5Y cells into neurons with
retinoic acid (Encinas et al., 2000). Full details onmaintenance, neuronal differ-
entiation, proliferation, and cell survival are presented in Supplemental Exper-
imental Procedures.
SNORD116 Cluster Deletion Using CRISPR-Cas9
We applied a cloning-free CRISPR protocol using gBlocks (gene fragments)
encoding FE-modified single guide RNAs (sgRNAs) promoting enhanced sta-
bility (Arbab et al., 2015). Two gBlocks carrying the guide flanking the
SNORD116 cluster on chr15q11.2 were nucleofected alongsideGFP-express-
ing Cas9 plasmid PX458into the SH-SY5Y line. Fluorescence-activated cell
sorting (FACS)-sorted cells were screened for successful editing using con-
ventional PCR and confirmed by Sanger sequencing. Full details are presented
in Supplemental Experimental Procedures.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism version 6.0 for
MacOS X. Data are represented as mean ± SEM. A two-tailed Student’s un-
paired t test was used, and p values < 0.05 were considered to indicate statis-
tical significance.DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA sequencing data reported in
this paper is EGA: EGAS00001002901.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and four tables and can be found with this article online at
https://doi.org/10.1016/j.celrep.2018.03.018.
ACKNOWLEDGMENTS
The authors would like to thank the donors, their families, and the staff of the
University of Maryland Brain Bank and the PWS patients and parents from the
Dutch PWS cohort studies. Human tissue was obtained from University of
Maryland Brain and Tissue Bank, which is a Brain and Tissue Repository of
the NIH NeuroBioBank. We thank the core facility at UCL, the Cambridge Na-
tional Institute of Health Research (NIHR) Biomedical Research Centre (BRC)
core laboratory, and the Children’s Hospital Los Angeles (CHLA) histology
core. We also thank Professor Mark Lalande (University of Connecticut) for
sharing the RNA-seq data from iPSC-derived neuronal cell lines. This work
was supported by the Wellcome Trust (098497/Z/12/Z), the NIHR Cambridge
Biomedical Research Centre, and the Bernard Wolfe Health Neuroscience
Endowment (all to I.S.F.), the NIH (grants DK84142 and DK102780 to
S.G.B.), the Foundation for Prader-Willi Research (to S.G.B.), a Society for
Endocrinology early career grant (to E.G.B.), and a Royal Society research
grant (RG160311 to E.G.B.). J.H. is funded by a Medical Research Council
(MRC) studentship grant number (516700).
AUTHOR CONTRIBUTIONS
E.G.B. and I.S.F. conceived and directed the study. E.G.B., K.L., K.K.L., J.H.,
and V.P. carried out the RNA sequencing and all downstream analysis. S.C.
and S.G.B. performed the in situ hybridization and immunohistochemical ex-
periments and analyses. N.P. and E.G.B. performed the functional experi-
ments on SNORD116. G.S. and E.G.B. performed the in silico SNORD116
work. J.M.K., I.S.F., A.H.-K., L.D., and S.D. recruited patients and controls
and contributed to the analysis of human samples. All authors analyzed and
interpreted the results. E.G.B., K.L., and I.S.F. wrote the manuscript with con-
tributions from all authors.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: December 7, 2017
Revised: February 7, 2018
Accepted: March 5, 2018
Published: March 27, 2018
REFERENCES
Andermann, M.L., and Lowell, B.B. (2017). Toward a wiring diagram under-
standing of appetite control. Neuron 95, 757–778.
Arbab, M., Srinivasan, S., Hashimoto, T., Geijsen, N., and Sherwood, R.I.
(2015). Cloning-free CRISPR. Stem Cell Reports 5, 908–917.
Atasoy, D., Betley, J.N., Su, H.H., and Sternson, S.M. (2012). Deconstruction
of a neural circuit for hunger. Nature 488, 172–177.
Barres, B.A. (2008). The mystery and magic of glia: a perspective on their roles
in health and disease. Neuron 60, 430–440.
Bazeley, P.S., Shepelev, V., Talebizadeh, Z., Butler, M.G., Fedorova, L., Fila-
tov, V., and Fedorov, A. (2008). snoTARGET shows that human orphan
snoRNA targets locate close to alternative splice junctions. Gene 408,
172–179.Cell Reports 22, 3401–3408, March 27, 2018 3407
Betley, J.N., Cao, Z.F., Ritola, K.D., and Sternson, S.M. (2013). Parallel, redun-
dant circuit organization for homeostatic control of feeding behavior. Cell 155,
1337–1350.
Blalock, E.M., Geddes, J.W., Chen, K.C., Porter, N.M., Markesbery, W.R., and
Landfield, P.W. (2004). Incipient Alzheimer’s disease: microarray correlation
analyses reveal major transcriptional and tumor suppressor responses.
Proc. Natl. Acad. Sci. U S A 101, 2173–2178.
Bouret, S.G., Draper, S.J., and Simerly, R.B. (2004). Trophic action of leptin on
hypothalamic neurons that regulate feeding. Science 304, 108–110.
Burnett, L.C., Hubner, G., LeDuc, C.A., Morabito, M.V., Carli, J.F.M., and Leibel,
R.L. (2017a). Loss of the imprinted, non-coding Snord116 gene cluster in the in-
terval deleted in the Prader Willi syndrome results in murine neuronal and endo-
crine pancreatic developmental phenotypes. Hum. Mol. Genet. 26, 4606–4616.
Burnett, L.C., LeDuc, C.A., Sulsona, C.R., Paull, D., Rausch, R., Eddiry, S.,
Carli, J.F., Morabito, M.V., Skowronski, A.A., Hubner, G., et al. (2017b). Defi-
ciency in prohormone convertase PC1 impairs prohormone processing in
Prader-Willi syndrome. J. Clin. Invest. 127, 293–305.
Campbell, J.N., Macosko, E.Z., Fenselau, H., Pers, T.H., Lyubetskaya, A.,
Tenen, D., Goldman, M., Verstegen, A.M., Resch, J.M., McCarroll, S.A.,
et al. (2017). A molecular census of arcuate hypothalamus and median
eminence cell types. Nat. Neurosci. 20, 484–496.
Cassidy, S.B., Schwartz, S., Miller, J.L., and Driscoll, D.J. (2012). Prader-Willi
syndrome. Genet. Med. 14, 10–26.
Cowley, M.A., Pronchuk, N., Fan, W., Dinulescu, D.M., Colmers, W.F., and
Cone, R.D. (1999). Integration of NPY, AGRP, and melanocortin signals in
the hypothalamic paraventricular nucleus: evidence of a cellular basis for the
adipostat. Neuron 24, 155–163.
Cowley, M.A., Smart, J.L., Rubinstein, M., Cerda´n, M.G., Diano, S., Horvath,
T.L., Cone, R.D., and Low, M.J. (2001). Leptin activates anorexigenic POMC
neurons through a neural network in the arcuate nucleus. Nature 411, 480–484.
de Smith, A.J., Purmann, C., Walters, R.G., Ellis, R.J., Holder, S.E., Van Haelst,
M.M.,Brady,A.F., Fairbrother,U.L.,Dattani,M.,Keogh,J.M., et al. (2009). Adele-
tionof theHBII-85classof small nucleolarRNAs (snoRNAs) isassociatedwithhy-
perphagia, obesity and hypogonadism. Hum. Mol. Genet. 18, 3257–3265.
Encinas, M., Iglesias, M., Liu, Y., Wang, H., Muhaisen, A., Cen˜a, V., Gallego,
C., and Comella, J.X. (2000). Sequential treatment of SH-SY5Y cells with
retinoic acid and brain-derived neurotrophic factor gives rise to fully
differentiated, neurotrophic factor-dependent, human neuron-like cells.
J. Neurochem. 75, 991–1003.
Falaleeva, M., Surface, J., Shen, M., de la Grange, P., and Stamm, S. (2015).
SNORD116 and SNORD115 change expression of multiple genes and modify
each other’s activity. Gene 572, 266–273.
Gautron, L., Elmquist, J.K., andWilliams, K.W. (2015). Neural control of energy
balance: translating circuits to therapies. Cell 161, 133–145.
Gray, J., Yeo, G.S., Cox, J.J., Morton, J., Adlam, A.L., Keogh, J.M., Yanovski,
J.A., El Gharbawy, A., Han, J.C., Tung, Y.C., et al. (2006). Hyperphagia, severe
obesity, impaired cognitive function, and hyperactivity associated with func-
tional loss of one copy of the brain-derived neurotrophic factor (BDNF) gene.
Diabetes 55, 3366–3371.
Griffin, W.S., Stanley, L.C., Ling, C.,White, L., MacLeod, V., Perrot, L.J., White,
C.L., 3rd, and Araoz, C. (1989). Brain interleukin 1 and S-100 immunoreactivity
are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci.
U S A 86, 7611–7615.
Han, J.C., Muehlbauer, M.J., Cui, H.N., Newgard, C.B., and Haqq, A.M. (2010).
Lower brain-derived neurotrophic factor in patients with prader-willi syndrome
compared to obese and lean control subjects. J. Clin. Endocrinol. Metab. 95,
3532–3536.
Hendricks, A.E., Bochukova, E.G., Marenne, G., Keogh, J.M., Atanassova, N.,
Bounds, R., Wheeler, E., Mistry, V., Henning, E., Ko¨rner, A., et al.; Understand-
ing Society Scientific Group; EPIC-CVD Consortium; UK10K Consortium
(2017). Rare variant analysis of human and rodent obesity genes in individuals
with severe childhood obesity. Sci. Rep. 7, 4394.3408 Cell Reports 22, 3401–3408, March 27, 2018Henry, F.E., Sugino, K., Tozer, A., Branco, T., and Sternson, S.M. (2015). Cell
Type-Specific Transcriptomics of Hypothalamic Energy-Sensing Neuron
Responses to Weight-Loss (Cambridge: Elife), p. 4.
Ishigaki, S.,Masuda, A., Fujioka, Y., Iguchi, Y., Katsuno,M., Shibata, A., Urano,
F., Sobue, G., and Ohno, K. (2012). Position-dependent FUS-RNA interactions
regulate alternative splicing events and transcriptions. Sci. Rep. 2, 529.
Kishore, S., and Stamm, S. (2006). The snoRNA HBII-52 regulates alternative
splicing of the serotonin receptor 2C. Science 311, 230–232.
Lu, T., Pan, Y., Kao, S.Y., Li, C., Kohane, I., Chan, J., and Yankner, B.A. (2004).
Gene regulation and DNA damage in the ageing human brain. Nature 429,
883–891.
Manning, K.E., and Holland, A.J. (2015). Puzzle pieces: neural structure and
function in Prader-Willi syndrome. Diseases 3, 382–415.
Newman, A.M., Liu, C.L., Green, M.R., Gentles, A.J., Feng, W., Xu, Y., Hoang,
C.D., Diehn, M., and Alizadeh, A.A. (2015). Robust enumeration of cell subsets
from tissue expression profiles. Nat. Methods 12, 453–457.
O’Rahilly, S., and Farooqi, I.S. (2008). Human obesity as a heritable disorder of
the central control of energy balance. Int. J. Obes. 32 (Suppl 7), S55–S61.
Parikshak, N.N., Swarup, V., Belgard, T.G., Irimia, M., Ramaswami, G., Gan-
dal, M.J., Hartl, C., Leppa, V., Ubieta, L.T., Huang, J., et al. (2016). Genome-
wide changes in lncRNA, splicing, and regional gene expression patterns in
autism. Nature 540, 423–427.
Polex-Wolf, J., Lam, B.Y., Larder, R., Tadross, J., Rimmington, D., Bosch, F.,
Cenzano, V.J., Ayuso, E., Ma, M.K., Rainbow, K., et al. (2018). Hypothalamic
loss of Snord116 recapitulates the hyperphagia of Prader-Willi syndrome.
J. Clin. Invest. 128, 960–969.
Resnick, J.L., Nicholls, R.D., andWevrick, R. (2013). Recommendations for the
investigation of animal models of Prader-Willi syndrome. Mamm. Genome 24,
165–178.
Rogelj, B., Easton, L.E., Bogu, G.K., Stanton, L.W., Rot, G., Curk, T., Zupan, B.,
Sugimoto, Y., Modic, M., Haberman, N., et al. (2012). Widespread binding of
FUS along nascent RNA regulates alternative splicing in the brain. Sci. Rep.
2, 603.
Sahoo, T., del Gaudio, D., German, J.R., Shinawi, M., Peters, S.U., Person,
R.E., Garnica, A., Cheung, S.W., and Beaudet, A.L. (2008). Prader-Willi pheno-
type caused by paternal deficiency for the HBII-85 C/D box small nucleolar
RNA cluster. Nat. Genet. 40, 719–721.
Snider, W.D. (1994). Functions of the neurotrophins during nervous system
development: what the knockouts are teaching us. Cell 77, 627–638.
Sternson, S.M., Atasoy, D., Betley, J.N., Henry, F.E., and Xu, S. (2016). An
emerging technology framework for the neurobiology of appetite. Cell Metab.
23, 234–253.
Swaab, D.F., Purba, J.S., and Hofman, M.A. (1995). Alterations in the hypotha-
lamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in
Prader-Willi syndrome: a study of five cases. J. Clin. Endocrinol. Metab. 80,
573–579.
Tauber, M., Boulanouar, K., Diene, G., C¸abal-Berthoumieu, S., Ehlinger, V., Fi-
chaux-Bourin, P., Molinas, C., Faye, S., Valette, M., Pourrinet, J., et al. (2017).
The use of oxytocin to improve feeding and social skills in infants with Prader-
Willi syndrome. Pediatrics 139, e20162976.
Terajima, H., Yoshitane, H., Ozaki, H., Suzuki, Y., Shimba, S., Kuroda, S., Iwa-
saki,W., and Fukada, Y. (2017). ADARB1 catalyzes circadian A-to-I editing and
regulates RNA rhythm. Nat. Genet. 49, 146–151.
van der Klaauw, A.A., and Farooqi, I.S. (2015). The hunger genes: pathways to
obesity. Cell 161, 119–132.
Yeo, G.S., Connie Hung, C.C., Rochford, J., Keogh, J., Gray, J., Sivaramak-
rishnan, S., O’Rahilly, S., and Farooqi, I.S. (2004). A de novomutation affecting
human TrkB associated with severe obesity and developmental delay. Nat.
Neurosci. 7, 1187–1189.
Yin, Q.F., Yang, L., Zhang, Y., Xiang, J.F., Wu, Y.W., Carmichael, G.G., and
Chen, L.L. (2012). Long noncoding RNAs with snoRNA ends. Mol. Cell 48,
219–230.
